PARP1BCR::ABL1 p190+

Caio Bezerra Machado1, Emerson Lucena da Silva1, Wallax Augusto Silva Ferreira2

  • 1Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza 60430-275, CE, Brazil.

Cancers
|December 9, 2023
PubMed
概括

聚 ((ADP-ribose) 聚合酶抑制剂在治疗费城染色体阳性急性淋巴细胞白血病 (Ph+ ALL) 中表现有前途. 用AZD2461准PARP在模型中显示出有效性,为这种具有挑战性的白血病提供了潜在的新治疗策略.